39 results on '"West, Michael L."'
Search Results
2. Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease
3. Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry
4. Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
5. Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products
6. Lentivirus-mediated gene therapy for Fabry disease
7. Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
8. Additional file 1 of Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
9. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease
10. Gender-specific plasma proteomic biomarkers in patients with Anderson–Fabry disease
11. Uncertain Diagnosis of Fabry Disease in Patients with Neuropathic Pain, Angiokeratoma or Cornea Verticillata: Consensus on the Approach to Diagnosis and Follow-Up
12. Primary Hyperoxaluria Type 1 (PH1) Presenting With End-Stage Kidney Disease and Cutaneous Manifestations in Adulthood: A Case Report
13. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis
14. Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative
15. Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres
16. Renal-Limited Antiglomerular Basement Membrane Disease Related To Alemtuzumab: A Case Report
17. Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
18. The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process.
19. Cardio-renal outcomes with long-term alfa enzyme replacement therapy : a 10-year Fabry outcome survey (FOS) analysis
20. Patients with Fabry disease on dialysis in the United States
21. FP114RENOPROTECTIVE EFFECT OF AGALSIDASE ALFA IN FABRY DISEASE IS INDEPENDENT OF TYPE OF MUTATION: RESULTS OF 12-YEAR FOLLOW-UP
22. Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction
23. Long-term outcomes with agalsidase alfa enzyme replacement therapy : analysis using deconstructed composite events
24. Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events
25. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
26. Prevalence of Fabry Disease and Outcomes in Young Canadian Patients With Cryptogenic Ischemic Cerebrovascular Events
27. Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34 + Cells for Correction of Fabry Disease
28. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
29. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease.
30. Total synthesis of (pm)-calanolide A, a non-nucleoside inhibitor of HIV-1 reverse transcriptase
31. Cardiovascular Events in Patients With Fabry Disease
32. Therapeutic goals in the treatment of Fabry disease
33. Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literature
34. CARDIOVASCULAR EVENTS IN PATIENTS WITH FABRY DISEASE: NATURAL HISTORY DATA FROM THE FABRY REGISTRY
35. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease
36. Total synthesis of (.+-.)-calanolide A, a non-nucleoside inhibitor of HIV-1 reverse transcriptase
37. Cardiovascular Events in Patients With Fabry Disease Natural History Data From the Fabry Registry
38. A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis
39. Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.